Literature DB >> 10890322

Complex management issues: management of HCV in the atypical patient.

S J Hadziyannis1, D Vassilopoulos.   

Abstract

Some patients with chronic hepatitis C virus (HCV) infection demonstrate atypical features of presentation and clinical course. These features may be due to direct or indirect effects of the underlying HCV infection or may be part of a separate clinical syndrome. Patients that can be categorized as 'atypical' include immunosuppressed individuals (hypogammaglobulinaemic, co-infected with human immunodeficiency virus, recipients of solid organ or haematopoietic cell transplants, those with associated disease requiring chronic immunosuppressive therapy and patients with chronic renal failure on haemodialysis) as well as patients with various extra-hepatic (HCV-associated mixed cryoglobulinaemia, membranoproliferative glomerulonephritis etc) or autoimmune manifestations. Since many of these patients have been excluded from the large trials evaluating the efficacy of interferon-alpha alone or in combination with ribavirin, data regarding management are limited. In this chapter, the available information regarding the treatment of these patients is reviewed and the frequently encountered therapeutic dilemmas discussed. Finally, some reasonable therapeutic approaches are suggested while the need for controlled studies for these groups of patients is emphasized.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10890322     DOI: 10.1053/bega.1999.0076

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Gastroenterol


  2 in total

Review 1.  Rheumatic manifestations of hepatitis C infection.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Curr Rheumatol Rep       Date:  2003-06       Impact factor: 4.592

Review 2.  Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review.

Authors:  Ashwani-K Singal; Bhupinderjit S Anand
Journal:  World J Gastroenterol       Date:  2009-08-14       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.